Flavokawain A is primarily studied for its potential anticancer properties. It has shown activity against various cancer cell lines, including breast, prostate, liver, and colon cancers, by inducing apoptosis and inhibiting cell cycle progression. Research indicates it may suppress tumor growth by modulating signaling pathways such as NF-κB, PI3K/Akt, and MAPK. It also exhibits anti-inflammatory and antioxidant effects, which contribute to its therapeutic potential in chronic diseases. In addition, Flavokawain A has been investigated for its ability to sensitize cancer cells to conventional chemotherapy, suggesting a role as an adjuvant in cancer treatment. Due to its natural origin and bioactivity, it is explored in nutraceutical and pharmaceutical development, though its use remains largely in the preclinical research stage. Challenges such as low bioavailability and solubility are being addressed through formulation studies like nanoparticle delivery systems.